Cardiovascular disease is a major killer in women yet is frequently considered a male-dominated disease. The risk of cardiovascular disease in women is frequently underestimated and there is also considerable evidence of a treatment bias against women. Women are generally underrepresented in cardiovascular clinical trials yet there is evidence of gender-specific differences in the responses to pharmacotherapy. The Sibutramine Cardiovascular Outcomes (SCOUT) trial has been designed to determine whether weight management with sibutramine together with a diet-and exercise-based lifestyle intervention can prevent cardiovascular morbidity and mortality in high-risk overweight and obese patients. The SCOUT population includes a large number of older women, at high risk for cardiovascular disease. Data from the trial's lead-in phase indicate that treatment with sibutramine and lifestyle management for 6 weeks result in clinically important weight loss and reduction in waist circumference. Despite an initial lower body weight, older women with cardiovascular disease and diabetes mellitus appear to lose as much weight as men. In the overall SCOUT population, treatment with sibutramine is associated with small median decreases in systolic and diastolic blood pressure and small median increases in pulse rate. The side-effect profile of sibutramine in this older, 'at-risk' population was similar to that previously observed in younger patients.
Cardiovascular disease is the leading cause of death for both men and women. Data from the World Health Organization showing cause of death by gender in the European countries for 2004 illustrate that coronary heart disease (CHD), stroke and other cardiovascular diseases were responsible for 43% of all deaths in men and for 56% of all deaths in women. 1 While CHD represents 21% of deaths in men and 23% in women, stroke is a relatively more frequent cause of death in women than in men (18 and 11%, respectively), as is also true for other cardiovascular disease (15% in women and 11% in men). By way of comparison, it is interesting to note that breast cancer, commonly misperceived as the leading cause of morbidity and mortality among women, accounts for only 3% of all deaths. 2 Both the prevalence and incidence of cardiovascular disease among both men and women increase with age. 3 However, while the prevalence of cardiovascular disease is lower in women when compared with men in younger age groups, the gender difference narrows at older ages. The gender difference is further decreased by the fact that life expectancy is greater in women.
Nevertheless, the risk of heart disease in women is frequently underestimated because of the assumption that women are 'protected' against ischaemic heart disease. 2 While it is true that premenopausal women have a lower risk of cardiac events, this protection is lost after the menopause thus leaving women with untreated risk factors vulnerable to develop myocardial infarction, heart failure and sudden cardiac death.
Furthermore, clinical manifestations of cardiovascular disease as well as responses to therapy may be different in women from those commonly observed in men, which may further contribute to under-recognition of the disease. 2 The onset of heart disease is often more gradual in women than in men, and is accompanied by fatigue rather than by the commonly associated, sudden violent chest pain experienced by men. This may lead to under-recognition of symptoms and often, following an acute heart attack, to critical delays in treatment. Swedish studies suggest that women suspected of suffering a myocardial infarction wait longer than men from onset of pain to hospitalisation and receive a lower ambulance priority. 4 One example that highlights the gender-specific response to cardiovascular therapy is shown by the evaluation of the effectiveness of aspirin in primary prevention of myocardial infarction and stroke ( Figure 1) . A meta-analysis of data from the Women's Health Study and from trials involving mostly men with no history of heart disease indicated that aspirin therapy reduced the risk of stroke but did not affect the occurrence of myocardial infarction in women. 5 By contrast, in men, aspirin significantly reduced the risk of myocardial infarction with a nonsignificant increase in the risk of stroke. The reasons for these differential effects of aspirin in men and women are not yet clear but they do have important clinical implications and emphasise the need for an adequate representation of women in clinical trials. Studies looking at the use of thrombolytic agents show that they are consistently underused in eligible women compared to men. 6 It has also been suggested that b-blockers and aspirin are under-prescribed in females following myocardial infarction. 7, 8 In addition, several studies have indicated a statistically significant difference between men and women in the use of invasive procedures. 9, 10 Furthermore, a study conducted in a primary care setting suggests that while similar proportions of men and women were documented to have hyperlipidaemia, there was a 10% lower prescription rate for lipid-lowering agents in women than in men. 11 This suggests that women are not targeted as aggressively for secondary prevention as are men. This study also revealed greater aspirin usage by men. Perhaps more worryingly, there is evidence of a treatment bias against women with cardiovascular disease. 12 Women are more likely to receive in-hospital care from general physicians rather than cardiologists. Patients admitted by cardiologists have a significantly better survival rate than those admitted by primary care physicians. 13, 14 Therefore, there seems to be a perception both among the public and the medical profession of cardiovascular disease as a 'disease of men'. The result is that cardiovascular disease in women is under-diagnosed and under-treated. Women with cardiovascular disease are therefore more likely than men to die or suffer disability from a recurrent heart attack or heart failure. 2 
Rationale for obesity management
Current approaches to obesity management are based on substantial evidence to show that moderate weight loss can improve both metabolic and cardiovascular risk factors, 15 and good direct evidence to show that it can prevent progression from impaired glucose tolerance to overt diabetes mellitus. 16, 17 In addition, large epidemiological studies have shown that a healthy lifestyle is associated with a reduced cardiovascular morbidity and mortality, 18 while analyses of prospective data have indicated that modest intentional weight loss may be associated with reduced premature mortality. 19, 20 Anti-obesity agents produce and maintain moderate weight loss in a greater number of patients than those treated with diet and lifestyle interventions alone. 21 Furthermore, this weight loss is frequently associated with additional beneficial changes in cardiovascular and metabolic risk factors, such as dyslipidaemia. These improvements relate, in part, to the weight loss produced and in part to specific properties of the weight loss drugs themselves.
The main unanswered question, and perhaps the principal barrier to wider use of weight loss agents in clinical practice, is the practical demonstration of whether or not the use of these drugs can prevent cardiovascular morbidity and mortality.
The Sibutramine Cardiac Outcomes (SCOUT) trial is the first large-scale randomised trial designed to assess whether sibutramine-assisted weight loss can be superior to diet and exercise interventions alone in reducing cardiovascular morbidity and mortality in overweight and obese patients at markedly increased risk of cardiovascular events. 22 
Design and conduct of the SCOUT trial
The SCOUT trial is being conducted at 300 centres in 16 countries, predominantly within Europe. The design of the trial has been previously reported and is summarised in Figure 2 .
Following a 2-week screening phase, patients enter a 6-week, single-blind, lead-in phase during which all are treated with sibutramine 10 mg daily and a specially designed diet and exercise programme tailored to the individual patient and based on achieving a daily deficit of 600 kcal together with more than 150 min of moderate exercise per week. This lead-in phase was included as a safety measure because of early concerns regarding the potential effects of sibutramine as a serotonin and norepinephrine reuptake inhibitor on blood pressure and heart rate. It also permits an assessment of compliance; patients who take less than 85% of study drug Figure 1 Gender-specific effects of aspirin on primary prevention of myocardial infarction and stroke (adapted from Ridker et al.
)
The obese older female patient WF Coutinho during this phase are not eligible for further inclusion in the trial. To assess susceptibility to sibutramine-induced hypertension, patients were not allowed to change their hypotensive therapy during this 6-week test period.
Following completion of the lead-in phase, eligible patients are then randomised to sibutramine (10 mg daily with the option to increase to 15 mg) or placebo together with the individualised diet and exercise programme.
SCOUT is an event-driven study and it is anticipated that a sufficient number of endpoint events is unlikely to accumulate before a minimum patient follow-up of 3 years.
The SCOUT population is one that has not previously been studied in relation to sibutramine treatment. They are, in general, an older population than previously studied: entry criteria required patients to be above 55 years of age, an age group usually under-represented in trials of obesity management. In addition to overweight/obese patients with BMI 427-45 kg/m 2 , patients with a lower degree of overweight (BMI 25-27 kg/m 2 ) than previously studied were included if they also had central adiposity as evidenced by an increased waist circumference (X102 cm for men and X88 cm for women). Importantly, patients also had to fall into one of the following three risk categories: Documented cardiovascular disease (prior myocardial infarction, prior coronary revascularisation or otherwise proven atherosclerotic disease such as peripheral arterial occlusive disease or stroke) but excluding type 2 diabetes (CV only). Type 2 diabetes with at least one additional risk factor such as controlled hypertension, dyslipidaemia, current smoker or diabetic neuropathy, but no history of prior cardiovascular disease (DM only).
Documented cardiovascular disease (prior myocardial infarction, prior coronary revascularisation or otherwise proven atherosclerotic disease such as peripheral arterial occlusive disease or stroke) together with type 2 diabetes and another risk factor (CV þ DM).
The SCOUT population is, therefore, quite different from that eligible to receive sibutramine under current licensing arrangements.
The SCOUT lead-in phase
When SCOUT was originally planned, it was thought that as many as 25% of the high-risk patients who enrolled might be discontinued during the 6-week, lead-in phase when all patients received treatment with sibutramine 10 mg. The patient population to be enrolled in SCOUT were already at high cardiovascular risk and treatment with sibutramine could have increased this risk. However, more patients than anticipated successfully completed this lead-in phase.
The screening/week-6 demographic data of the 10 742 patients who entered the lead-in phase of the SCOUT trial have been described previously. 23 Data on these patients who received sibutramine 10 mg together with advice for lifestyle show that after 6 weeks treatment, there were small but clinically relevant and statistically significant changes in anthropomorphic variables and vital signs (Figure 3) . 24 Body weight was reduced by 2.2 kg, waist circumference by 2 cm, systolic blood pressure by 3 mm Hg, and diastolic blood pressure by 1 mm Hg, although heart rate rose by 1.5 b.p.m. (Po0.001 for each variable) ( Table 1) . Adverse events leading to discontinuation The obese older female patient WF Coutinho were low and similar to those reported previously with sibutramine therapy. Only 2.9% of patients in this very high-risk population reported one or more serious adverse events, while just 2.7% of patients discontinued due to an adverse event. In terms of cardiac safety, the percentage of serious adverse events was 1% and included atrial fibrillation, unstable angina and angina pectoris. The rate and number of serious adverse events was lower than had been predicted, leaving the trial with a larger cohort at the end of the 6-week lead-in phase to go into the randomisation phase.
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Gender comparisons in the SCOUT lead-in phase
In general, weight loss trials tend to recruit a larger number of women than men. However, the SCOUT trial is well balanced in terms of gender, which means that it offers a unique opportunity to study how men and women may differ in response to a pharmacological approach to weight management. Women comprised 42% of the total population and although the median body weight of men was higher, women had higher BMI values at inclusion (35.1 vs 32.9 kg/m 2 ). Women also had a relatively high initial median waist circumference of 109.0 cm indicating an increased visceral adiposity. About two-thirds of the overall population (n ¼ 6397; 59.6%) had both established cardiovascular disease and type 2 diabetes mellitus (CV þ DM risk group) and were, therefore, at very high risk for future cardiovascular events. Over half of the women (51.3%, n ¼ 2321) fell into this very high-risk category and may be considered to represent a metabolically challenged population.
Among these high-risk patients with both diabetes and pre-existing cardiovascular disease, the 6-week treatment period with sibutramine and weight management resulted in clinically important reductions in body weight in both men and women with median weight changes of À2.6% in women and À2.2% in men. This degree of weight loss is particularly noteworthy as it is well recognised that patients with diabetes commonly experience greater difficulty in losing weight compared with those without diabetes.
Median waist circumference fell by 2 cm for both men and women from screening to baseline, indicating a loss of abdominal fat tissue.
Safety parameters during the 6-week lead-in period are of particular interest in this high-risk group. Therefore, it was reassuring to note that in both men and women, there was a fall in median SBP of approx. 3.0 mm Hg from screening to baseline. Over the same period, there was a fall in diastolic blood pressure of about 1.0 mm Hg. However, this was accompanied by a slight increase in pulse rate, consistent with the known mechanism of action of sibutramine. For men there was a rise in pulse rate of 2.0 b.p.m. from screening to baseline, while for women the mean rise in pulse rate was 1.5 b.p.m.
Summary
Treatment with sibutramine and lifestyle management for 6 weeks resulted in clinically important weight loss and waist reduction.
Despite an initial lower body weight, women lost as much weight as men.
The overall side-effect profile of sibutramine in this older, 'at-risk' population was similar to that previously observed in younger patients.
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